ArticlePloS one2012
Use of cell-SELEX to generate DNA aptamers as molecular probes of HPV-associated cervical cancer cells.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 60 citations in OpenAlex.
- Analysis of quadruplex propensity of aptamer sequences.Nucleic acids research · 2025Article
- Recent advances in aptamer-based biosensing technology for isolation and detection of extracellular vesicles.Frontiers in cell and developmental biology · 2025Review
- Advances in Aptamers-Based Applications in Breast Cancer: Drug Delivery, Therapeutics, and Diagnostics.International journal of molecular sciences · 2022Review
- In Vitro Selection of a DNA Aptamer by Cell-SELEX as a Molecular Probe for Cervical Cancer Recognition and Imaging.Journal of molecular evolution · 2019Article
- Recent Advances in Aptamer Discovery and Applications.Molecules (Basel, Switzerland) · 2019Review
- Nucleic acid aptamer-based methods for diagnosis of infections.Biosensors & bioelectronics · 2018Review
- Development of Cell-Specific Aptamers: Recent Advances and Insight into the Selection Procedures.Molecules (Basel, Switzerland) · 2017Review
- Nucleic acid aptamer application in diagnosis and therapy of colorectal cancer based on cell-SELEX technology.NPJ precision oncology · 2017Review
- Use of Aptamers as Diagnostics Tools and Antiviral Agents for Human Viruses.Pharmaceuticals (Basel, Switzerland) · 2016Review
- Application of aptamers in diagnostics, drug-delivery and imaging.Journal of biosciences · 2016Article
- Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer.Pharmaceuticals (Basel, Switzerland) · 2016Article
- Subtractive Cell-SELEX Selection of DNA Aptamers Binding Specifically and Selectively to Hepatocellular Carcinoma Cells with High Metastatic Potential.BioMed research international · 2016Article
- Microfluidic chip system for the selection and enrichment of cell binding aptamers.Biomicrofluidics · 2015Article
- Review
- Single-Stranded DNA Aptamers against Pathogens and Toxins: Identification and Biosensing Applications.BioMed research international · 2015Review
- Characterization of an RNA aptamer against HPV-16 L1 virus-like particles.Nucleic acid therapeutics · 2014Article
- Aptamers: multifunctional molecules for biomedical research.Journal of molecular medicine (Berlin, Germany) · 2013Review
- DNA aptamers that target human glioblastoma multiforme cells overexpressing epidermal growth factor receptor variant III in vitro.Acta pharmacologica Sinica · 2013Article
- Aptamer-based therapeutics: new approaches to combat human viral diseases.Pharmaceuticals (Basel, Switzerland) · 2013Article
- Identification of RNA aptamers that internalize into HPV-16 E6/E7 transformed tonsillar epithelial cells.Virology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundDisease-specific biomarkers are an important tool for the timely and effective management of pathological conditions, including determination of susceptibility, diagnosis, and monitoring efficacy of preventive or therapeutic strategies. Aptamers, comprising single-stranded or double-stranded DNA or RNA, can serve as biomarkers of disease or biological states. Aptamers can bind to specific epitopes on macromolecules by virtue of their three dimensional structures and, much like antibodies, aptamers can be used to target specific epitopes on the basis of their molecular shape. The Systematic Evolution of Ligands by EXponential enrichment (SELEX) is the approach used to select high affinity aptamers for specific macromolecular targets from among the >10(13) oligomers comprising typical random oligomer libraries. In the present study, we used live cell-based SELEX to identify DNA aptamers which recognize cell surface differences between HPV-transformed cervical carcinoma cancer cells and isogenic, nontumorigenic, revertant cell lines. METHODOLOGY/PRINCIPAL
findingsWhole-cell SELEX methodology was adapted for use with adherent cell lines (which we termed Adherent Cell-SELEX (AC-SELEX)). Using this approach, we identified high affinity aptamers (nanomolar range K(d)) to epitopes specific to the cell surface of two nontumorigenic, nontumorigenic revertants derived from the human cervical cancer HeLa cell line, and demonstrated the loss of these epitopes in another human papillomavirus transformed cervical cancer cell line (SiHa). We also performed preliminary investigation of the aptamer epitopes and their binding characteristics. CONCLUSIONS/SIGNIFICANCE: Using AC-SELEX we have generated several aptamers that have high affinity and specificity to the nontumorigenic, revertant of HPV-transformed cervical cancer cells. These aptamers can be used to identify new biomarkers that are related to carcinogenesis. Panels of aptamers, such as these may be useful in predicting the tumorigenic potential and properties of cancer biopsies and aid in the effective management of pathological conditions (diagnosis, predicted outcome, and treatment options).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.